MBRC 101
Alternative Names: MBRC-101Latest Information Update: 18 Jun 2024
At a glance
- Originator MBrace Therapeutics
- Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Breast cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics from a preclinical study in lung cancer as well as breast, pancreatic, gastric, and colorectal cancer were presented at 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 07 Dec 2023 Pharmacodynamics and adverse events data from preclinical trial in Solid tumours released by MBrace Therapeutics
- 05 Dec 2023 Preclinical trials in Breast cancer in USA (Parenteral) before December 2023